Journal of Clinical Virology
Volume 46 , Pages S64-S67 , December 2009

CMV vaccine trial endpoints

  • P.D. Griffiths

      Affiliations

    • Corresponding Author InformationTel.: +44 020 7830 2997; fax: +44 020 7830 2854.

Received 7 May 2009 ,Revised 5 October 2009 ,Accepted 6 October 2009.

References 

  1. Stratton KR, Durch JS, Lawrence RS. Vaccines for the 21st century. Washington, DC: National Academy Press; 2000;
  2. Plotkin SA, Higgins R, Kurtz JB, Morris PJ, Campbell DA, Shope TC, et al. Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients. Transplantation. 1994;58:1176–1178
  3. Emery VC, Cope AV, Bowen EF, Gor D, Griffiths PD. The dynamics of human cytomegalovirus replication in vivo. J Exp Med. 1999;190:177–182
  4. Pass RF, Zhang C, Evans A, Simpson T, Andrews W, Huang M-L, et al. Vaccine Prevention of Maternal Cytomegalovirus Infection. N Engl J Med. 2009;360:1191–1199
  5. Griffiths PD, McLean A, Emery VC. Encouraging prospects for immunisation against primary cytomegalovirus infection. Vaccine. 2001;19:1356–1362
  6. Colugnati FA, Staras SA, Dollard SC, Cannon MJ. Incidence of cytomegalovirus infection among the general population and pregnant women in the United States. BMC Infect Dis. 2007;7:71
  7. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6:271–278
  8. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, et al. Sustained efficacy up to 4, 5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367:1247–1255
  9. West RR, McNabb R, Thompson AG, Sheldon TA, Grimley EJ. Estimating implied rates of discount in healthcare decision-making. Health Technol Assess. 2003;7:1–60
  10. Kenneson A, Cannon MJ. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol. 2007;17:253–276
  11. Dollard SC, Grosse SD, Ross DS. New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev Med Virol. 2007;17:355–363
  12. Snydman DR. The case for cytomegalovirus prophylaxis in solid organ transplantation. Rev Med Virol. 2006;16:289–295
  13. Singh N. Antiviral drugs for cytomegalovirus in transplant recipients: advantages of preemptive therapy. Rev Med Virol. 2006;16:281–287
  14. Lowance D, Neumayer HH, Legendre CM, Squifflet JP, Kovarik J, Brennan PJ, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med. 1999;340:1462–1470
  15. van Hamont D, Bekkers RL, Massuger LF, Melchers WJ. Detection, management, and follow-up of pre-malignant cervical lesions and the role for human papillomavirus. Rev Med Virol. 2008;18:117–132
  16. Schiller JT, Castellsagué X, Villa LL, Hildesheim A. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine. 2008;26S:K53–K61

PII: S1386-6532(09)00493-4

doi: 10.1016/j.jcv.2009.10.003

Journal of Clinical Virology
Volume 46 , Pages S64-S67 , December 2009

Article Tools

* Image Usage & Resolution